Immune Reconstitution and Vaccinations in Multiple Myeloma: A Report From the 19th International Myeloma Society Annual Workshop
Clin Lymphoma Myeloma Leuk. 2023 Mar 23:S2152-2650(23)00106-4. doi: 10.1016/j.clml.2023.03.009. Online ahead of print.ABSTRACTGiven the significance of the immune system and the important role of therapies within the context of the immune system in plasma cell disorders, the International Myeloma Society annual workshop convened a session dedicated to this topic. A panel of experts covered various aspects of immune reconstitution and vaccination. The top oral presentations were highlighted and discussed. This is a report of the proceedings.PMID:37055346 | DOI:10.1016/j.clml.2023.03.009 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - April 13, 2023 Category: Cancer & Oncology Authors: Evangelos Terpos Paola Neri Niels W C J van de Donk Mattia D'Agostino Samir Parekh Sundar Jagannath Heinz Ludwig David E Avigan Madhav V Dhodapkar Noopur S Raje Source Type: research
Increasing FDA Accelerated approval of Single-Arm Trials in Oncology (1992 to 2020)
CONCLUSION: The granting of FDA-AAs based on SAT in oncology is increasing with more target drugs approved over time. Transparency in historical control reporting is necessary.PMID:37037322 | DOI:10.1016/j.jclinepi.2023.04.001 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - April 10, 2023 Category: Cancer & Oncology Authors: Tatiane Bomfim Ribeiro Charles L Bennett Luis Enrique Colunga-Lozano Ana Paula Vieira Araujo Iztok Hozo Benjamin Djulbegovic Source Type: research
Increasing FDA Accelerated approval of Single-Arm Trials in Oncology (1992 to 2020)
CONCLUSION: The granting of FDA-AAs based on SAT in oncology is increasing with more target drugs approved over time. Transparency in historical control reporting is necessary.PMID:37037322 | DOI:10.1016/j.jclinepi.2023.04.001 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - April 10, 2023 Category: Cancer & Oncology Authors: Tatiane Bomfim Ribeiro Charles L Bennett Luis Enrique Colunga-Lozano Ana Paula Vieira Araujo Iztok Hozo Benjamin Djulbegovic Source Type: research
Increasing FDA Accelerated approval of Single-Arm Trials in Oncology (1992 to 2020)
CONCLUSION: The granting of FDA-AAs based on SAT in oncology is increasing with more target drugs approved over time. Transparency in historical control reporting is necessary.PMID:37037322 | DOI:10.1016/j.jclinepi.2023.04.001 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - April 10, 2023 Category: Cancer & Oncology Authors: Tatiane Bomfim Ribeiro Charles L Bennett Luis Enrique Colunga-Lozano Ana Paula Vieira Araujo Iztok Hozo Benjamin Djulbegovic Source Type: research
Management of Chronic Myeloid Leukemia Patients in Later Lines: The Role of Ponatinib and New Compounds
Clin Lymphoma Myeloma Leuk. 2023 Mar 20:S2152-2650(23)00089-7. doi: 10.1016/j.clml.2023.03.004. Online ahead of print.ABSTRACTLimited therapeutic options and poor response probability still represent some unresolved issue in later lines chronic myeloid leukemia (CML) patients. In addition, sequential treatment is associated with reduced overall survival and may select new mutation, including the T315I, further reducing the therapeutic chances: outside the United States, ponatinib and allogenic stem cell transplant are the only available options. In the last decade, ponatinib improved outcomes in third-line patients, althou...
Source: Clinical Lymphoma and Myeloma - April 7, 2023 Category: Cancer & Oncology Authors: Emilia Scalzulli Ida Carmosino Alessandro Costa Maria Laura Bisegna Maurizio Martelli Massimo Breccia Source Type: research
Management of Chronic Myeloid Leukemia Patients in Later Lines: The Role of Ponatinib and New Compounds
Clin Lymphoma Myeloma Leuk. 2023 Mar 20:S2152-2650(23)00089-7. doi: 10.1016/j.clml.2023.03.004. Online ahead of print.ABSTRACTLimited therapeutic options and poor response probability still represent some unresolved issue in later lines chronic myeloid leukemia (CML) patients. In addition, sequential treatment is associated with reduced overall survival and may select new mutation, including the T315I, further reducing the therapeutic chances: outside the United States, ponatinib and allogenic stem cell transplant are the only available options. In the last decade, ponatinib improved outcomes in third-line patients, althou...
Source: Clinical Lymphoma and Myeloma - April 7, 2023 Category: Cancer & Oncology Authors: Emilia Scalzulli Ida Carmosino Alessandro Costa Maria Laura Bisegna Maurizio Martelli Massimo Breccia Source Type: research
Management of Chronic Myeloid Leukemia Patients in Later Lines: The Role of Ponatinib and New Compounds
Clin Lymphoma Myeloma Leuk. 2023 Mar 20:S2152-2650(23)00089-7. doi: 10.1016/j.clml.2023.03.004. Online ahead of print.ABSTRACTLimited therapeutic options and poor response probability still represent some unresolved issue in later lines chronic myeloid leukemia (CML) patients. In addition, sequential treatment is associated with reduced overall survival and may select new mutation, including the T315I, further reducing the therapeutic chances: outside the United States, ponatinib and allogenic stem cell transplant are the only available options. In the last decade, ponatinib improved outcomes in third-line patients, althou...
Source: Clinical Lymphoma and Myeloma - April 7, 2023 Category: Cancer & Oncology Authors: Emilia Scalzulli Ida Carmosino Alessandro Costa Maria Laura Bisegna Maurizio Martelli Massimo Breccia Source Type: research
Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS Study
CONCLUSION: D-VMP demonstrated a favorable benefit/risk profile in transplant-ineligible Asian NDMM patients. This trial was registered at www.CLINICALTRIALS: gov as #NCT03217812.PMID:37024420 | DOI:10.1016/j.clml.2023.02.009 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - April 6, 2023 Category: Cancer & Oncology Authors: Weijun Fu Soo-Mee Bang Honghui Huang Kihyun Kim Wei Li Gang An Je-Jung Lee Zhen Cai Jie Jin Yafei Wang Tung-Liang Lin Chor Sang Chim Ming Qi Jianping Wang Xiaolin Lu Yang Song Bin Jia Xue Yang Wenyu Liu Tianyuan Zhou Lu Yin Yunan Li Renyi Zhang Jian Hou J Source Type: research
Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS Study
CONCLUSION: D-VMP demonstrated a favorable benefit/risk profile in transplant-ineligible Asian NDMM patients. This trial was registered at www.CLINICALTRIALS: gov as #NCT03217812.PMID:37024420 | DOI:10.1016/j.clml.2023.02.009 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - April 6, 2023 Category: Cancer & Oncology Authors: Weijun Fu Soo-Mee Bang Honghui Huang Kihyun Kim Wei Li Gang An Je-Jung Lee Zhen Cai Jie Jin Yafei Wang Tung-Liang Lin Chor Sang Chim Ming Qi Jianping Wang Xiaolin Lu Yang Song Bin Jia Xue Yang Wenyu Liu Tianyuan Zhou Lu Yin Yunan Li Renyi Zhang Jian Hou J Source Type: research
Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma
Clin Lymphoma Myeloma Leuk. 2023 Mar 7:S2152-2650(23)00076-9. doi: 10.1016/j.clml.2023.03.002. Online ahead of print.ABSTRACTCOVID-19 adversely affects individuals with cancer. Several studies have found that seroconversion rates among patients with hematologic malignancies are suboptimal when compared to patients without cancer. Patients with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM) are immunocompromised due to impaired humoral and cellular immunity in addition to prescribed immunosuppressive therapy. Chimeric antigen receptor T-cell (CAR T) therapy is now widely used for NHL and MM, but little is known about ...
Source: Clinical Lymphoma and Myeloma - April 1, 2023 Category: Cancer & Oncology Authors: Julia E Wiedmeier-Nutor Madiha Iqbal Allison C Rosenthal Evandro D Bezerra Juan Esteban Garcia-Robledo Radhika Bansal Patrick B Johnston Matthew Hathcock Jeremy T Larsen P Leif Bergsagel Yucai Wang Craig B Reeder Jose F Leis Rafael Fonseca Jeanne M Palmer Source Type: research
Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma
Clin Lymphoma Myeloma Leuk. 2023 Mar 7:S2152-2650(23)00076-9. doi: 10.1016/j.clml.2023.03.002. Online ahead of print.ABSTRACTCOVID-19 adversely affects individuals with cancer. Several studies have found that seroconversion rates among patients with hematologic malignancies are suboptimal when compared to patients without cancer. Patients with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM) are immunocompromised due to impaired humoral and cellular immunity in addition to prescribed immunosuppressive therapy. Chimeric antigen receptor T-cell (CAR T) therapy is now widely used for NHL and MM, but little is known about ...
Source: Clinical Lymphoma and Myeloma - April 1, 2023 Category: Cancer & Oncology Authors: Julia E Wiedmeier-Nutor Madiha Iqbal Allison C Rosenthal Evandro D Bezerra Juan Esteban Garcia-Robledo Radhika Bansal Patrick B Johnston Matthew Hathcock Jeremy T Larsen P Leif Bergsagel Yucai Wang Craig B Reeder Jose F Leis Rafael Fonseca Jeanne M Palmer Source Type: research
Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma
Clin Lymphoma Myeloma Leuk. 2023 Mar 7:S2152-2650(23)00076-9. doi: 10.1016/j.clml.2023.03.002. Online ahead of print.ABSTRACTCOVID-19 adversely affects individuals with cancer. Several studies have found that seroconversion rates among patients with hematologic malignancies are suboptimal when compared to patients without cancer. Patients with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM) are immunocompromised due to impaired humoral and cellular immunity in addition to prescribed immunosuppressive therapy. Chimeric antigen receptor T-cell (CAR T) therapy is now widely used for NHL and MM, but little is known about ...
Source: Clinical Lymphoma and Myeloma - April 1, 2023 Category: Cancer & Oncology Authors: Julia E Wiedmeier-Nutor Madiha Iqbal Allison C Rosenthal Evandro D Bezerra Juan Esteban Garcia-Robledo Radhika Bansal Patrick B Johnston Matthew Hathcock Jeremy T Larsen P Leif Bergsagel Yucai Wang Craig B Reeder Jose F Leis Rafael Fonseca Jeanne M Palmer Source Type: research
Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma
Clin Lymphoma Myeloma Leuk. 2023 Mar 7:S2152-2650(23)00076-9. doi: 10.1016/j.clml.2023.03.002. Online ahead of print.ABSTRACTCOVID-19 adversely affects individuals with cancer. Several studies have found that seroconversion rates among patients with hematologic malignancies are suboptimal when compared to patients without cancer. Patients with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM) are immunocompromised due to impaired humoral and cellular immunity in addition to prescribed immunosuppressive therapy. Chimeric antigen receptor T-cell (CAR T) therapy is now widely used for NHL and MM, but little is known about ...
Source: Clinical Lymphoma and Myeloma - April 1, 2023 Category: Cancer & Oncology Authors: Julia E Wiedmeier-Nutor Madiha Iqbal Allison C Rosenthal Evandro D Bezerra Juan Esteban Garcia-Robledo Radhika Bansal Patrick B Johnston Matthew Hathcock Jeremy T Larsen P Leif Bergsagel Yucai Wang Craig B Reeder Jose F Leis Rafael Fonseca Jeanne M Palmer Source Type: research
Patient Confidence and Information Preferences During the Treatment Decision-making Process: Results From a Large Multiple Myeloma Patient Survey Across 12 Countries in Europe and Israel
CONCLUSION: Over half of patients felt very confident in their latest treatment decision; however, patients reported not routinely receiving important treatment effectiveness information. Addressing the discrepancies between information that patients receive and consider important may enhance confidence in decision-making.PMID:36967243 | DOI:10.1016/j.clml.2023.02.010 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 26, 2023 Category: Cancer & Oncology Authors: Ulf-Henrik Mellqvist H Tilman Steinmetz Aurore Perrot Erik Aerts Paul Williams Ana Vallejo Kate Morgan Ananda Plate Ana Mar ía Rodríguez-Leboeuf Renaud Desgraz Eva Hellqvist Franck Lucy De Costa Alessandra Brescianini Heinz Ludwig Source Type: research
Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma
CONCLUSION: Teclistamab showed significantly improved effectiveness versus PC on all outcomes, highlighting its clinical benefit in patients with TCE RRMM and limited treatment options.PMID:36967244 | DOI:10.1016/j.clml.2023.02.006 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 26, 2023 Category: Cancer & Oncology Authors: Mar ía-Victoria Mateos Ajai Chari Saad Z Usmani Hartmut Goldschmidt Katja Weisel Keqin Qi Anil Londhe Sandhya Nair Xiwu Lin Lixia Pei Eric Ammann Rachel Kobos Jennifer Smit Trilok Parekh Alexander Marshall Mary Slavcev Philippe Moreau Source Type: research
